Treatment for pancreatic cancer depends primarily on whether the tumor can be surgically removed, and most treatment plans involve some combination of surgery, chemotherapy, and radiation. Only about 15 to 20 percent of patients are candidates for surgery at the time of diagnosis, so chemotherapy is the backbone of treatment for the majority. The five-year survival rate ranges dramatically by stage: 43.6% for cancers caught while still localized, 17% when the cancer has reached nearby lymph nodes, and 3.4% when it has spread to distant organs.
How Doctors Determine Your Treatment Path
Before recommending treatment, your medical team classifies the tumor into one of four categories based on imaging. These categories determine everything that follows.
- Resectable: The tumor can be surgically removed. You will likely receive chemotherapy before or after surgery to improve outcomes.
- Borderline resectable: A surgeon would have difficulty safely removing all the cancer. Treatment to shrink the tumor comes first, and surgery is reconsidered afterward.
- Locally advanced: The tumor has grown into nearby blood vessels in a way that makes surgery impossible for now. It hasn’t spread to distant organs, though, and some people become surgical candidates after other treatments shrink the tumor.
- Metastatic: The cancer has spread to other organs, most commonly the liver or lungs. Surgery to remove the primary tumor is not an option, and treatment focuses on extending life and managing symptoms.
The distinction between these categories comes down to how much the tumor touches or wraps around critical arteries and veins near the pancreas. Even a few degrees of contact with a major blood vessel can shift a tumor from “removable” to “not removable,” which is why imaging is so critical early on.
Surgery: The Only Potential Cure
Surgery offers the best chance of long-term survival, but the specific operation depends on where the tumor sits in the pancreas.
Tumors in the head of the pancreas (the most common location) are treated with a Whipple procedure, formally called a pancreatoduodenectomy. This is a major operation that removes part of the pancreas, part of the small intestine, the gallbladder, the common bile duct, nearby lymph nodes, and sometimes part of the stomach. The remaining organs are then reconnected so that digestion can continue. Recovery typically takes several weeks, and many patients need time to adjust to changes in digestion afterward.
Tumors in the body or tail of the pancreas are treated with a distal pancreatectomy, which removes the body and tail of the pancreas along with the spleen. This is generally a less complex operation than the Whipple, with a somewhat shorter recovery.
In some cases, a total pancreatectomy is necessary, removing the entire pancreas, spleen, gallbladder, parts of the stomach and small intestine, and nearby lymph nodes. Because the pancreas produces insulin, people who have a total pancreatectomy will need to manage diabetes with insulin for the rest of their lives.
Chemotherapy Before and After Surgery
Almost all patients with pancreatic cancer receive chemotherapy at some point. For surgical candidates, chemotherapy is commonly given before surgery (to shrink the tumor and treat any microscopic cancer cells that may have already spread) and again after surgery to reduce the risk of recurrence.
Two regimens dominate first-line treatment. FOLFIRINOX, a combination of four drugs, offers the strongest survival benefit. In clinical trials, it reduced the risk of death at 12 months from about 77% to 52% compared to older single-drug treatment. The tradeoff is a higher rate of serious side effects, including fatigue, nausea, diarrhea, and a drop in infection-fighting white blood cells. FOLFIRINOX is generally reserved for patients who are in good overall health and can tolerate an aggressive regimen.
The second major option pairs gemcitabine with nab-paclitaxel. This combination also provides a significant survival improvement, reducing 12-month mortality from about 77% to 64%. It carries a different side effect profile and is sometimes better tolerated than FOLFIRINOX, making it a common choice for patients who are older or have other health conditions. Research suggests FOLFIRINOX may have a slight edge in survival over gemcitabine-based regimens, though both remain standard options.
Radiation Therapy
Radiation plays a more targeted role in pancreatic cancer than chemotherapy does. It is most often used alongside chemotherapy for borderline resectable or locally advanced tumors, with the goal of shrinking the cancer enough to make surgery possible, or to control local tumor growth.
Stereotactic body radiation therapy (SBRT) has become an increasingly popular approach. It delivers high doses of precisely focused radiation in just one to five sessions, compared to the five or six weeks of daily treatments required by traditional radiation. Early evidence suggests SBRT may be more effective against tumors than conventional radiation while carrying a lower risk of damage to surrounding tissue. Its short treatment window also makes it far more practical for patients who are managing the physical toll of a cancer diagnosis.
Intensity-modulated radiation therapy (IMRT) is another technique that shapes radiation beams to conform to the tumor’s contours, helping to spare nearby healthy organs like the stomach and kidneys.
Targeted Therapy and Genetic Testing
A small but meaningful percentage of pancreatic cancers carry specific genetic mutations that can be targeted with precision drugs. This is why genetic testing of the tumor (and sometimes the patient’s own DNA) has become a standard part of the diagnostic workup.
Patients whose tumors have mutations in the BRCA1, BRCA2, or PALB2 genes may benefit from a class of drugs called PARP inhibitors. These drugs exploit a weakness in the cancer cell’s ability to repair its own DNA, causing the cells to die. BRCA mutations are perhaps best known in breast and ovarian cancers, but the same mutations appear in a subset of pancreatic cancers and open the door to this treatment.
Other rare but actionable mutations include KRAS G12C and fusions involving genes called NTRK and NRG1. Drugs targeting these alterations are approved regardless of where the cancer originated in the body, a concept known as “tumor-agnostic” treatment. While only a small fraction of pancreatic cancer patients carry these mutations, for those who do, the drugs can be remarkably effective.
Immunotherapy: Effective for Very Few
Immunotherapy has transformed treatment for many cancers, but pancreatic cancer has been one of the most resistant. The exception is a small group, roughly 1 to 2 percent of patients, whose tumors show a specific molecular feature called mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H). These tumors accumulate many mutations, which makes them more visible to the immune system when given a boost from immunotherapy drugs.
For this small group, immune checkpoint inhibitors are now recommended over standard chemotherapy. Research from the Mayo Clinic supports using immunotherapy as the preferred systemic treatment for any patient with a dMMR or MSI-H pancreatic tumor, whether the cancer is metastatic or being treated before or after surgery. For the other 98% of patients, immunotherapy alone has not shown meaningful benefit, though clinical trials are exploring combinations that might change this.
Managing Symptoms and Quality of Life
Pancreatic cancer often causes debilitating symptoms even before treatment begins, and palliative care, focused on comfort and function, is an important part of the plan at every stage.
One of the most common problems is bile duct blockage. When a tumor presses on the bile duct, it causes jaundice, itching, and pain. Doctors can relieve this by placing a stent, a small tube inserted through an endoscope, to reopen the duct and restore bile flow. Plastic stents are used as a short-term solution, often when surgery is still planned. Metal stents are more permanent and are placed when the blockage needs a longer-lasting fix.
Pain is a major concern, particularly as the disease advances. When medications alone are not enough, a procedure called a celiac plexus block can help. This involves injecting a nerve-blocking agent into the cluster of nerves behind the pancreas that transmit pain signals, providing significant relief for many patients.
Digestive Enzyme Replacement
The pancreas produces enzymes essential for digesting fats, proteins, and starches. When a tumor disrupts this function, or when surgery removes part or all of the pancreas, patients develop difficulty absorbing nutrients. Symptoms include oily or foul-smelling stools, bloating, weight loss, and cramping after meals.
Pancreatic enzyme replacement capsules taken with meals restore much of this digestive function. The typical starting dose for someone with complete loss of enzyme production (after total pancreatectomy, for example) is 500 lipase units per kilogram of body weight per meal. In practice, most people start with one capsule of a lower-dose formulation every 10 minutes while eating and adjust from there. These enzymes aren’t needed for simple snacks like fruit, juice, or non-starchy vegetables like lettuce and cucumbers, since those foods don’t require much pancreatic enzyme activity to digest.
What the Survival Numbers Mean
Pancreatic cancer survival statistics are sobering but shifting. According to SEER data covering 2016 through 2022, the five-year relative survival rate is 43.6% for localized disease, 17% for regional disease that has reached nearby lymph nodes, and 3.4% for distant metastatic disease. These numbers represent averages across all patients diagnosed during that period, including those treated with older regimens. Newer chemotherapy combinations, expanded use of genetic testing, and improvements in surgical technique are all contributing to incremental gains, particularly for the subset of patients whose tumors are caught early or who carry targetable mutations.
Stage at diagnosis remains the single most important factor. Unfortunately, only a small minority of pancreatic cancers are found while still localized, which is the primary reason overall survival rates remain low compared to many other cancers.